Finding the right Brixadi treatment in Maryland takes more than a Google search. Fentanyl now drives the overwhelming majority of opioid overdose deaths in the state, and every week spent on a waiting list or chasing down the wrong provider is a week of unnecessary risk. This guide covers what Brixadi actually is, how to verify that a provider can deliver it, and what separates a program worth your time from one that will waste it.
What Brixadi Actually Is and How It Works
Brixadi is a subcutaneous buprenorphine injectable, FDA-approved in 2023, designed to deliver a sustained, consistent level of buprenorphine without requiring daily dosing. The medication is injected just beneath the skin, typically in the upper arm or abdomen, where it releases buprenorphine gradually over the course of days or weeks depending on the formulation used. That steady-state delivery is the core clinical advantage: rather than peaks and troughs tied to whether you remembered to take a film that morning, your buprenorphine level stays relatively flat across the dosing interval.
The mechanism is the same as other buprenorphine formulations. Buprenorphine is a partial opioid agonist that binds with high affinity to mu-opioid receptors, blunting cravings and blocking the effects of other opioids without producing the same degree of euphoria as full agonists like heroin or oxycodone. The pivotal Phase 3 clinical trial published in JAMA Network Open (2021, n=428) demonstrated that extended-release buprenorphine produced significantly greater treatment retention and more opioid-negative urine samples compared to placebo, with a responder rate of 52.8% versus 22.3% in the control group. That trial laid the groundwork for Brixadi’s FDA approval and established the evidence base for what providers now offer in-office.
For someone switching from Suboxone or starting treatment for the first time, what this means in practice is straightforward: the daily ritual of dissolving a film under your tongue goes away. The medication is administered by a provider at the clinic, which removes the variables of daily adherence and eliminates diversion risk entirely.
How Brixadi Differs from Other Buprenorphine Formulations
Sublingual buprenorphine films and tablets (Suboxone, Subutex, generic equivalents) require daily administration. Miss a dose and your buprenorphine level drops, which opens a window for cravings and withdrawal discomfort. The injectable format closes that window by design.
Brixadi is available in both weekly and monthly injectable doses, which is one of its defining features compared to the once-monthly Sublocade. That weekly option matters in early treatment: it gives providers the ability to adjust dosing more frequently while a patient is finding the right level, then transition to monthly injections once things are stable. If you want to understand the mechanics of how the weekly injection format works in practice, that distinction between the two schedules is worth reading before your first provider call.
A 2019 study published in Drug and Alcohol Dependence analyzing adherence across buprenorphine formulations found that injectable formats produced substantially better adherence rates than oral formulations, particularly among patients with a history of inconsistent daily medication use. The takeaway for your decision-making: if you’ve tried sublingual buprenorphine and found daily dosing difficult to maintain, an injectable formulation addresses the specific mechanism of that failure.
One concrete action before you call any provider: ask whether they stock both the weekly and monthly Brixadi formulations. Some clinics carry only one. The flexibility to move between schedules as your treatment progresses is a meaningful clinical advantage, and a clinic that only offers one format limits your options from the start.
Who Qualifies for Brixadi
The clinical eligibility criteria for Brixadi are specific. Patients must first be established on a stable dose of transmucosal buprenorphine, which means you need to have been taking sublingual buprenorphine for a period sufficient to confirm tolerability and dose requirements before receiving the first injection. Patients who are currently in precipitated withdrawal or have never taken buprenorphine are not candidates for an immediate first injection.
The patient populations that benefit most from Brixadi include people with a documented history of inconsistent oral medication adherence, individuals in early recovery with elevated relapse risk who would benefit from the certainty of a provider-administered dose, and patients managing co-occurring mental health conditions who are already navigating multiple appointments and medication regimens. Maryland Medicaid covers Brixadi as a medication for opioid use disorder, which makes it accessible for a large portion of the state’s treatment-seeking population. Commercial insurance plans vary in their coverage, but prior authorization pathways exist for most major carriers.
Why Maryland’s Opioid Crisis Makes This Search Urgent
Maryland recorded 2,583 overdose deaths in 2022, according to the Maryland Department of Health’s Overdose Data Dashboard. Fentanyl or fentanyl analogs were present in more than 90% of those deaths. The pace has not meaningfully slowed since then. What that number represents in practical terms is this: the window between deciding to seek treatment and actually starting medication is the highest-risk interval in someone’s recovery. Delays of even a few days carry measurable mortality risk.
The reason this is relevant to your search for Brixadi treatment in Maryland specifically is that not every provider who prescribes buprenorphine can actually administer Brixadi. Knowing which clinics offer the injectable format before you start calling eliminates the wasted time of appointments with providers who will ultimately send you elsewhere. That saved time is not a convenience issue. It is a clinical one.
How to Verify a Provider Is Actually Certified to Prescribe Brixadi
Since the federal government eliminated the DATA 2000 waiver requirement in early 2023, any licensed prescriber can technically prescribe buprenorphine without completing a separate certification process. According to SAMHSA’s 2023 implementation guidance on the waiver elimination, this change was intended to dramatically expand access. And it has, for sublingual formulations. But Brixadi is not a prescription you fill at a pharmacy. The clinic administers the injection on-site, which means the provider needs specific training in the injectable protocol, appropriate cold storage equipment for the medication, and the clinical staff and scheduling infrastructure to support regular injection visits.
The waiver removal does not resolve those logistical requirements. A provider can be fully authorized to prescribe buprenorphine and still have no capacity to administer Brixadi. That gap is why verifying a provider’s actual capability matters more than confirming their prescribing authorization.
When calling a clinic, ask three questions directly. First, do you administer Brixadi injections in-office? Second, do you stock both the weekly and monthly formulations? Third, how soon can you schedule a first injection appointment? Those three questions tell you everything you need to know about whether a provider is operationally set up to treat you. If any answer is vague or deflective, move to the next clinic.
Using SAMHSA’s Treatment Locator the Right Way
SAMHSA’s findtreatment.gov and the Buprenorphine Practitioner Locator are legitimate starting points, but they require interpretation. According to SAMHSA’s 2024 National Survey on Drug Use and Health (n=73,561), approximately 6.1 million people aged 12 and older needed but did not receive treatment for opioid use disorder in the past year. The treatment locator exists to help close that gap, but it lists buprenorphine prescribers broadly, not Brixadi-specific providers. A physician who prescribes Suboxone films appears on that list. A clinic that administers injectable Brixadi also appears on that list. The database does not distinguish between them.
The practical move: use the locator to generate a list of five to ten providers near your Maryland location, then call each one with the three verification questions above. Do not schedule any appointment before confirming injectable availability. The list is a starting point, not a vetted directory. If you want a shortcut on finding injection-capable providers in your area, that resource filters specifically for clinics set up to administer the injectable format.
What Maryland-Specific Resources to Use
Maryland’s 211 system connects callers to behavioral health treatment referral specialists who often have more current information about which providers are actively accepting new patients than national databases do. The Maryland Behavioral Health Administration maintains provider directories that are updated more frequently than federal locators, and the Maryland Opioid Operational Command Center (OOCC) publishes county-level treatment data that can help you identify where access gaps exist and where capacity is available.
The Maryland Medicaid landscape for medications for opioid use disorder is relatively favorable. The state has prioritized MOUD coverage as part of its overdose response strategy, and Brixadi is included in that coverage framework. State-level resources often reflect formulary and coverage changes faster than national databases, so a call to 211 Maryland before you start scheduling can save significant time on the back end.
What to Look for in a Brixadi Treatment Program
A 2020 study published in JAMA Psychiatry examining retention in medications for opioid use disorder programs (n=2,340) found that patients who remained in treatment for at least 12 months had a 70% lower mortality rate than those who left treatment within the first 90 days. Retention is the outcome that matters most, and retention is almost entirely determined by program quality. The medication itself is only part of what keeps someone in treatment.
What separates programs that support long-term recovery from those that produce early dropout comes down to a few observable factors: whether they offer integrated mental health support, whether their scheduling is realistic for working adults and people with transportation challenges, and whether their policies treat patients as people in recovery rather than liabilities to be managed. To understand the full scope of what a well-structured program actually includes, those three factors are worth examining before you commit to any clinic.
Integrated Mental Health and Co-Occurring Disorder Support
According to a 2021 study in JAMA Psychiatry examining 38,000 patients in opioid use disorder treatment, approximately 44% had at least one co-occurring psychiatric diagnosis, most commonly depression, anxiety disorders, or PTSD. Treating opioid use disorder in isolation from those conditions produces worse outcomes on both fronts.
What this means in practice: a program that only manages the Brixadi injection and offers no pathway to psychiatric care leaves a significant portion of patients underserved. When evaluating a clinic, ask directly whether psychiatric services are offered on-site or whether the provider has an established referral relationship with a behavioral health specialist. A warm referral, meaning the clinic coordinates the appointment rather than handing you a phone number, is meaningfully different from a list of suggestions. Programs that handle both within the same visit or same practice network reduce the friction that causes people to fall out of care.
Medicaid Acceptance and No-Insurance Options
Maryland Medicaid covers Brixadi as part of its covered medications for opioid use disorder, following the state’s commitment to MOUD access as a public health priority. For most Medicaid-covered patients, the injection itself and the associated clinical visits are reimbursable, though specific plan requirements around prior authorization vary by managed care organization.
For patients without insurance or with coverage gaps, two pathways exist. Sliding-scale fee structures are common among federally qualified health centers and some nonprofit treatment programs. Braeburn, the manufacturer of Brixadi, also operates a patient assistance program that can provide the medication at reduced or no cost for qualifying patients who lack coverage. Before your first appointment, call the billing department directly and ask two things: what documentation you need for Medicaid verification, and whether the clinic can help you apply for the manufacturer’s assistance program if your coverage has gaps. That single call can prevent insurance issues from delaying your start date.
Telehealth vs. In-Person Requirements
The DEA and HHS issued updated telemedicine rules for buprenorphine in 2023 that allow prescribers to initiate buprenorphine treatment via telehealth without an in-person visit in many circumstances. That flexibility has expanded access to sublingual buprenorphine meaningfully. But it does not apply to Brixadi in the same way.
The injection requires an in-person clinic visit. Full stop. Initial evaluations and ongoing counseling can often be conducted via telehealth, which reduces the burden of frequent travel. But the injection itself requires you to be physically present at a clinic where a trained provider administers it. If a telehealth-first provider implies they can manage your entire Brixadi treatment remotely, that is not accurate. Confirm before committing to any telehealth program that they have a physical injection site and that you understand exactly which appointments require in-person attendance.
Location and Scheduling Practicality Across Maryland
A 2021 study in the Journal of Substance Abuse Treatment (n=1,204) found that transportation barriers were among the top three reasons patients cited for missing medication appointments, with patients traveling more than 30 minutes to a clinic showing a 23% lower retention rate at six months compared to those within 15 minutes. Distance matters. But so does availability.
Patients across Maryland, whether in Baltimore, College Park, Linthicum Heights, Nottingham, or Owings Mills, face different access realities. A provider 45 minutes away that can schedule your first appointment within the week is almost always the better clinical choice compared to a provider six blocks away with a three-week wait. Ask about same-week appointment availability, whether the clinic offers evening or weekend hours, and whether they operate multiple locations that could offer more scheduling flexibility. When evaluating providers across the state, proximity alone should not be the deciding criterion. Availability and program quality together determine whether treatment actually starts.
Red Flags to Avoid When Choosing a Brixadi Provider
A 2019 study in Addiction analyzing dropout patterns across 47 opioid treatment programs (n=6,300) found that programs with punitive discharge policies, mandatory abstinence requirements before initiating medication, and rigid one-size-fits-all protocols had patient dropout rates 40% higher in the first 90 days than programs with flexible, patient-centered policies. The first phone call to a clinic is enough to surface most of these red flags if you know what to listen for.
Programs That Demand Abstinence Before Prescribing
This is medically indefensible and unfortunately still practiced. The American Society of Addiction Medicine’s Clinical Practice Guidelines, updated in 2020 and reaffirmed in subsequent revisions, are explicit: buprenorphine is the treatment for opioid use disorder, not a reward for achieving a period of abstinence first. Requiring someone to be clean for 30 days before starting medication is the equivalent of requiring a diabetic patient to normalize their blood sugar before prescribing insulin.
If a provider tells you to come back when you’ve been clean for a period of time before they’ll start you on medication, end that call and move to the next provider on your list. That is not a program applying evidence-based care. There is no version of that policy that is consistent with current clinical guidelines on opioid use disorder treatment.
Clinics That Don’t Offer Individualized Dosing
Brixadi is available in multiple dose strengths specifically because individual patients require different amounts to achieve adequate receptor occupancy and symptom control. The FDA-approved prescribing information for Brixadi describes an individualized titration approach, with dose adjustments based on clinical response. A program that starts every patient on the same protocol and never adjusts based on how you’re actually doing is not practicing evidence-based care.
Ask the clinic directly: do you adjust the injection dose based on individual patient response, or does everyone start and stay on the same protocol? The answer tells you immediately whether the provider is treating you as an individual or processing patients through a fixed template. A rigid one-size approach also signals that the provider probably lacks the clinical infrastructure to monitor patients closely enough to recognize when adjustment is warranted.
How to Start Brixadi Treatment in Maryland: The Practical Steps
A 2020 study in JAMA Psychiatry (n=38,000) found that patients who initiated medication for opioid use disorder within 72 hours of first contact with a treatment program had significantly better 6-month retention rates than those who waited more than a week. Time to treatment is itself a predictor of outcome. Every step in this process should be oriented toward compressing the timeline between your first call and your first injection.
If you’re trying to understand what the process looks like from a provider’s perspective as you evaluate your options, that context helps you ask better questions during your initial calls.
What to Expect at Your First Appointment
The clinical intake typically covers a detailed substance use history, a physical assessment, a review of current medications, and insurance verification. If you’re currently taking sublingual buprenorphine, tell the scheduling team your current dose when you book the appointment. The provider needs to select the appropriate Brixadi dose strength for your first injection based on your existing buprenorphine dose, and knowing that in advance allows them to have the right formulation ready.
Per the Brixadi prescribing information, patients receiving their first injection must either be mildly to moderately in withdrawal, confirmed using the Clinical Opiate Withdrawal Scale (COWS), or already stabilized on sublingual buprenorphine at an established dose. If you arrive at your first appointment in full withdrawal or without having taken buprenorphine recently, the clinical protocol may require adjustment. Being transparent about your current medication status during scheduling removes that uncertainty.
What Ongoing Treatment Looks Like
The rhythm of Brixadi treatment shifts over time. Weekly injections are typically the starting point, giving the provider the ability to assess your response and adjust the dose over the first few weeks before moving to monthly dosing once you’re stable. That early phase involves more frequent clinic visits, but those visits compress significantly once you transition to the monthly format.
According to SAMHSA’s Treatment Improvement Protocol 63 on medications for opioid use disorder, ongoing MOUD management should include regular clinical check-ins, substance use monitoring, and access to counseling or recovery support services alongside the medication component. Brixadi handles the medication delivery. The counseling and care coordination components are what the program structure around the injection provides. When evaluating a clinic, ask what those wrap-around services look like: is counseling included in the visit, or is it a separate referral? Are care coordinators available to help navigate insurance or recovery support services? Those questions tell you whether the program treats the injection as the whole treatment or as one part of a broader recovery plan.
For a more detailed look at what to ask before choosing a provider, there are specific questions worth having ready before your first conversation with any clinic.
What to Try This Week
Open SAMHSA’s Buprenorphine Practitioner Locator, set the location to your Maryland city or zip code, and generate a list of five nearby providers. Then call each one and ask these three questions: Do you administer Brixadi injections in-office? Do you accept Maryland Medicaid? How soon can you schedule a first appointment? That round of calls takes about 30 minutes. At the end of it, you’ll know which providers are actually set up to help you, which ones aren’t, and which one can get you started soonest. Book the appointment before you hang up the phone.